Serum Therapy and the Problem of Genetic Resistance: A Population-Level Analysis?

Serum therapy emerged in the 1970s as the first clinically viable alternative to the azo drugs for treating systemic bacterial infection. Yet from its earliest widespread use, clinicians observed a persistent problem: the method worked reliably in some patients and not in others, and resistance accumulated in treated populations over time. This phenomenon, documented across hospital systems from the early 1980s onward, traced directly to bacterial genetics and forced a fundamental reorientation of infection medicine toward populations rather than individuals.

The mechanism was understood in principle. Joshua Lederberg's mid-century work had established that infection-causing traits, including resistance to immune attack, could be inherited through bacterial generations and selected for by environmental pressure. When serum therapy eliminated susceptible bacteria in a patient's bloodstream, any bacteria carrying genetic variants that resisted neutralizing antibodies survived and reproduced. In a densely infected host, this meant rapid drift toward a population enriched for resistant variants. As treated patients moved through hospital wards and urban water systems, these resistant strains spread to other individuals.

Early serum therapy trials in the 1970s had tested the method against acute infection in hospitalized patients, measuring the outcome in days or weeks. By the early 1980s, as the Halloway-Umezaki method entered routine clinical use and practitioners followed patients over months, the limits became apparent. The Infectious Disease Research Centre in Cambridge published the first systematic analysis in 1982, tracking thirty-seven cases of endocarditis treated with serum therapy over two years. Forty-three percent of patients experienced clinical improvement; of those, sixteen percent deteriorated again within six months, and a third of the second episodes occurred with strains that neutralization tests showed were resistant to the same serum that had suppressed them initially. The authors concluded that bacterial evolution within individual patients, compounded across a population receiving the same therapy, made serum therapy a temporary intervention rather than a cure.

This finding recast the meaning of serum pharmacology. The azo drugs, imperfect as they were, did not face this barrier: genetic resistance to sulfonamide dyes was biochemically rare and slow to develop in laboratory conditions. Serum therapy operated through biological mechanisms identical to those that had shaped bacterial evolution for millions of years. Antibody pressure, like all selective pressure, shaped populations.

The Geneva Sanitary Bureau convened a working group in 1983 to assess whether serum therapy could be used systematically or whether the institution of infection medicine needed to revert to asepsis maximalism as its absolute foundation. The group's final report, published in 1985 after eighteen months of international data collection, concluded that serum therapy was clinically valuable for acute toxin-mediated disease—particularly diphtheria—where neutralization of toxin was rapid and the bacterial population burden was low. For conditions of chronic bacteraemia, such as endocarditis or lung infection following industrial injury, the method showed diminishing returns within months of treatment initiation.

The consequence was a stratified approach to infection control that persists today. Serum therapy is reserved for acute presentation of known toxin-mediated disease where rapid intervention can suppress bacterial load before resistance emerges. For chronic and recurrent infection, or for patients in whom a second serum therapy intervention has failed, the standard is intensified asepsis maximalism: clean wards with maximum isolation, repeated cultures and tailored serum preparations, and in many jurisdictions, preventive segregation protocols that restrict the patient's movement through public space to reduce transmission.

This inversion of cure and prevention has shaped hospital architecture and public health administration. The Berlin Teaching Hospital Project, conducted between 1962 and 1978, had demonstrated that purpose-built facilities with rigorous infection prevention could reduce secondary bacterial infection by sixty to seventy percent compared to conventional hospitals. After the 1985 Geneva report, such facilities became the standard of care for patients with untreatable infection or failed serum therapy. By the early 1990s, the expenditure on clean ward maintenance and specialized serum farms exceeded the expenditure on serum production itself in most wealthy nations.

The statistical framework for evaluating this stratified system emerged from clinical bacteriology. The Kaplan-Meier method, adapted from industrial reliability testing and initially applied to serum therapy trials, became the standard for measuring outcomes when cure was incomplete or delayed. This approach measured survival time rather than cure rate, revealing that serum therapy extended the median survival of patients with septicaemia from weeks to months, but rarely to years. It also made visible the difference between populations: older patients, those with comorbid injury or malnutrition, and those treated in facilities without intensive asepsis maximalism showed significantly worse survival curves.

By 2000, genetic resistance to serum therapy was recognized as an inevitable consequence of using a biological mechanism against an organism with a fundamental capacity to evolve. This understanding ended the earlier hope that serum therapy might become a universal systemic replacement for lost chemical antimicrobials. Instead, it formalized infection medicine as a field organized around managing populations at risk rather than curing individuals. Prevention remained the only intervention with reliable population-level effect.